Oulu, Finland, May 16, 2019 – Bittium exhibits its innovative products and solutions for neuroscience and neurophysiology at Post Cardiac Arrest Care 2019, on May 23-24 in Lund, Sweden. At the event Bittium exhibits the wireless Bittium BrainStatus™ EEG amplifier, electrode headband and software meant for real-time brain electrical activity monitoring and the waterproof Bittium Faros™ cardiac ECG signal measuring and monitoring devices and Bittium FastFix™ patch electrode for long term ECG measurement.
At the event Bittium presents also the comprehensive solution being developed in collaboration with Cerenion for monitoring the electrical activity of the brain (EEG) of intensive care patients. This is done by combining Bittium BrainStatus™, a wireless EEG-monitoring device designed for monitoring real-time electrical brain activity, with Cerenion’s innovative C-Trend analysis that helps to interpret the brain function of intensive care patients using a simple C-Trend Index, which is easy to follow. The purpose of the solution is to ease and speed up the work of the nursing staff at the intensive care unit.
Products and solutions exhibited at the event are:
Bittium Faros outpatient monitoring solutions include several software options for cardiac monitoring. The built-in arrhythmia detection algorithms on the Bittium Faros device are used for event recording and cardiac event monitoring. Bittium’s solutions enable the earlier discharge of patients and the ability to quickly react to detected arrhythmias faster.
More information on the offering: https://www.bittium.com/medical
Senior Vice President, Medical Technologies
Tel. +358 40 344 3507
Bittium specializes in the development of reliable, secure communications and connectivity solutions, leveraging its 30 year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. In the field of healthcare technology, Bittium offers solutions for the measurement and monitoring of biosignals in the areas of cardiology, neurophysiology, rehabilitation, occupational health and sports medicine. Net sales in 2018 were EUR 62.8 million and operating profit was EUR 2.8 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com